May 16th 2025
Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.
Lykos Therapeutics Reshuffles Board of Directors Following FDA Rejection of Midomafetamine Capsules
January 15th 2025During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder.